AI Article Synopsis
- Marginal zone lymphomas (MZL) are slow-growing B-cell lymphomas that typically have a good prognosis but lack extensive research on treatment options.
- A case study of a woman with MZL showed a slow progression over 9 years, where only actively progressing areas were treated with moderate-dose radiotherapy, leading to complete regression of those lesions.
- The findings suggest that moderate-dose radiotherapy is a safe and effective method for controlling local tumors in MZL patients.
Article Abstract
Background: Marginal zone lymphomas (MZL) are indolent B-cell lymphomas with variable symptoms related to lymphoma location. Patients with such lymphoma often have an excellent prognosis. Concerning treatment, no large prospective trials have been published, making therapeutic decisions difficult.
Case Report: The Authors present the case of a female patient with an MZL which was slowly progressive throughout 9 years after diagnosis. Only clearly progressive lymphoma manifestations were treated with moderate-dose radiotherapy (total doses between 30 and 40 Gy). All irradiated lesions showed a complete regression and relapses only occurred at non-irradiated sites. The performance status remains very good.
Conclusion: Moderate-dose radiotherapy is a safe and effective treatment to achieve local tumor control in patients with MZL.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Characterization of the adaptive immune response in a mouse model for HPV-positive head and neck squamous cell carcinoma with implications to human disease.
Cancer Immunol Immunother
January 2025
Department of Otorhinolaryngology, Head and Neck Surgery, Ulm University Medical Center, Ulm, Germany.
Head and neck squamous cell carcinoma (HNSCC) is the seventh most common cancer worldwide with a poor prognosis for survival. Risk factors include alcohol and tobacco abuse and infection with human papilloma virus (HPV). To enhance anti-tumor immune responses immunotherapeutic approaches are approved for recurrent metastatic disease but only approx.
View Article and Find Full Text PDFPurpose: To explore how serum diabetes autoantibodies are related to the development of early diabetic retinopathy in children with type 1 diabetes mellitus.
Methods: In this prospective and observational study, 62 patients with type 1 diabetes mellitus who had not yet developed clinical diabetic retinopathy were followed up for at least 5 years. Healthy volunteers aged 10 to 20 years were also included.
Low-density scalp electrical source imaging of the ictal onset zone network using source coherence maps.
Front Neurol
December 2024
Division of Neurology, Department of Pediatrics, McMaster Children's Hospital, Hamilton, ON, Canada.
Introduction: This study investigated low-density scalp electrical source imaging of the ictal onset zone and interictal spike ripple high-frequency oscillation networks using source coherence maps in the pediatric epilepsy surgical workup. Intracranial monitoring, the gold standard for determining epileptogenic zones, has limited spatial sampling. Source coherence analysis presents a promising new non-invasive technique.
View Article and Find Full Text PDFESR Essentials: imaging of lymphoma-practice recommendations by the European Society of Oncologic Imaging.
Eur Radiol
January 2025
Department of Radiology, NYU Grossman School of Medicine, New York, USA.
Imaging is used for lymphoma detection, Ann Arbor/Lugano staging, and treatment response assessment. [F]FDG PET/CT should be used for most lymphomas, including Hodgkin lymphoma, aggressive/high-grade Non-Hodgkin lymphomas (NHL) such as diffuse large B-cell lymphoma, and many indolent/low-grade NHLs such as follicular lymphoma. Apart from these routinely FDG-avid lymphomas, some indolent NHLs, such as marginal zone lymphoma, are variably FDG-avid; here, [F]FDG PET/CT is an alternative to contrast-enhanced CT at baseline and may be used for treatment response assessment if the lymphoma was FDG-avid at baseline.
View Article and Find Full Text PDFThe characterization of tumor immune microenvironment after neoadjuvant immunotherapy in head and neck squamous cell cancer using multiplex immunohistochemistry.
Oral Oncol
January 2025
Department of Head and Neck Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China. Electronic address:
Objective: Optimizing clinical decision-making in head and neck squamous cell carcinoma (HNSCC) is challenging due to the ambiguous understanding of the immune cell dynamics and immune checkpoints regulation in the disease after the administration of neoadjuvant immunotherapy (NIT).
Methods: HNSCC biopsy samples collected before and after the neoadjuvant treatment are classified into the pathologic response (PR) and the non-pathologic response (NPR) groups according to treatment responses and the expression of immune cells and checkpoints was labeled using multiplex immunohistochemistry (m-IHC).
Results: The populations of CD4 T cells, CD8 T cells, regulatory T cells (Treg), PD-1, and PD-L1 were particularly higher in the PR group than the NPR group in pre-treatment tissues, with the p-values of log-transformed positive cell density <0.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!